In this Pharmaceutical Executive exclusive, Bob Jansen, David Shulkin, Gen. Paul Funk (Ret.), and Maj. Gen. Dennis LeMaster ...

Mercalis and PharmaCord announced the completion of their merger. The new company is rebranding itself as Valeris, which will ...

Pharmaceutical Executive: What are the factors that are impacting the compounded semaglutide market? Ferrin Williams, PharmD: ...

Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil ...

As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient ...

SK Life Science launched its latest DTC advertising campaign for its seizure medication. 1 Road to Reduction is an ...

With uncertainty surrounding the future of government funding, the onus is being placed on the private sector to continue ...

Supernus Pharmaceuticals’ campaign aims to raise awareness about issues women face even getting diagnosed with ADHD.

The FDA has approved Roche’s Susvimo (ranibizumab injection) 100 mg/mL for treating patients with diabetic retinopathy (DR).

Deal includes VG-3927, a first-in-class TREM2 agonist aimed at advancing next-generation Alzheimer disease therapies.

Clearance of ASC50 paves the way for a Phase I trial in patients with mild-to-moderate plaque psoriasis.

Lilly is also developing oral therapies for its gastroenterology pipeline.